Gilead Files US Application For Bulevirtide In Severe Form Of Viral Hepatitis
Gilead Sciences Inc (NASDAQ:GILD) has submitted a marketing application to FDA for bulevirtide for injection (2 mg) for chronic hepatitis delta…
Gilead Reports Submission Of Its Biologics License Application To FDA For Bulevirtide Treatment For People Living With Chronic Hepatitis Delta
-- If Approved, Bulevirtide Will Be the First Treatment Option for Adult Patients in the U. S. With Chronic Hepatitis Delta Virus Infection With Compensated Liver Disease --
FOSTER CITY, Calif.--(BUSINESS WIRE)-- Gilead
Gilead Exercises Options To Three Arcus Biosciences Clinical-stage Programs And Adds Research Collaboration; Arcus To Receive Option Payments Totaling $725M
-- Gilead Exercises Options to Arcus's Anti-TIGIT Program (Domvanalimab and AB308), Etrumadenant (A2a/A2b Adenosine Receptor Antagonist) and Quemliclustat (Small Molecule CD73 Inhibitor) --
-- Arcus to Receive
Gilead Granted U.S. Patent ‘Antibodies that target HIV GP120 and methods of use’
https://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=5042&f=G&l=50&d=PTXT&p=101&S1=20211109&OS=20211109&RS=20211109
Will Pfizer Outgun Merck With Oral COVID-19 Pill?
Merck, Inc. (NYSE: MRK) is locking horns with peer Pfizer, Inc. (NYSE: PFE) in what could be termed as the battle supremacy in the COVID-19 treatment market.
NRx Pharma Stock Nosedives As FDA Strikes Off Its COVID-19 Drug Hopeful
The FDA has declined the emergency use authorization (EUA) for NRx Pharmaceuticals’ (NASDAQ:NRXP) Zyesami (aviptadil). The Company is developing aviptadil in collaboration…
Attention Biotech Investors: Mark Your Calendar For November PDUFA Dates
The loaded Prescription Drug User Fee Act (PDUFA) calendar for October produced mixed outcomes.
PDUFA dates are key binary events for biotech stocks that can move the needle in a big way. These are the dates by which the Food and Drug Administration is required to announce its decision regarding approvability/non-approvability of drugs.
The Week Ahead In Biotech (Oct. 31-Nov. 6): Earnings Pick Up Pace, Eton Awaits Seizure Drug Approval, Kidney Conference, More IPOs In The Pipeline
Biotech stocks rose a third week running in the week ending Oct. 29 amid positive reaction to earnings. Big pharma earnings were mostly better than expected.
The Daily Biotech Pulse: Gilead-Merck Collaborate For Breast Cancer Study, Decision Day For ANI Pharma, Pfizer Gets Canadian Regulatory Nod, 3 IPOs
Here's a roundup of top developments in the biotech space over the last 24 hours.
SVB Leerink Maintains Outperform on Gilead Sciences, Lowers Price Target to $75
SVB Leerink analyst Geoffrey Porges maintains Gilead Sciences (NASDAQ:GILD) with a Outperform and lowers the price target from $77 to $75.